NASDAQ: MAZEMaze Therapeutics Inc Stock
$23.86-0.41 (-1.69%)
Updated Jun 16, 2026
MAZE Price
$23.86
Fair Value Price
$3.86
Market Cap
$1.32B
52 Week Low
$9.83
52 Week High
$53.65
P/E
-9.62x
P/B
3.86x
P/S
80.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.00M
Earnings
-$122.54M
Gross Margin
100%
Operating Margin
-608.38%
Profit Margin
-612.7%
Debt to Equity
0.23
Operating Cash Flow
-$122M
Beta
0.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MAZE Overview
Maze Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the creation of precise small molecule medications for a range of ailments within the United States. Its primary therapeutic targets encompass renal, cardiovascular, and associated metabolic conditions, alongside obesity. The company's developmental pipeline highlights two leading drug candidates: MZE829, an oral small molecule engineered to inhibit apolipoprotein L1, which is currently in Phase II clinical studies for APOL1 kidney disease; and MZE782, another oral small molecule designed to block the solute transporter SLC6A19, presently in Phase I clinical evaluation for chronic kidney disease. The company, originally incorporated in 2017, adopted its current name, Maze Therapeutics, Inc., in September 2018, having previously been known as Modulus Therapeutics, Inc. It maintains its headquarters in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MAZE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MAZE
Ranked#117 of 462
Ranked#117 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important MAZE news, forecast changes, insider trades & much more!
MAZE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MAZE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MAZE ($23.86) is overvalued by 517.94% relative to our estimate of its Fair Value price of $3.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MAZE ($23.86) is not significantly undervalued (517.94%) relative to our estimate of its Fair Value price of $3.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MAZE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MAZE due diligence checks available for Premium users.
Valuation
MAZE fair value
Fair Value of MAZE stock based on Discounted Cash Flow (DCF)
Price
$23.86
Fair Value
$3.86
Overvalued by
517.94%
MAZE ($23.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MAZE ($23.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MAZE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MAZE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.62x
Industry
16.03x
Market
13.25x
MAZE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.86x
Industry
4.86x
MAZE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MAZE's financial health
Profit margin
Revenue
$20.0M
Net Income
-$24.2M
Profit Margin
-121%
MAZE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MAZE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$419.7M
Liabilities
$78.0M
Debt to equity
0.23
MAZE's short-term assets ($379.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MAZE's short-term assets ($379.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MAZE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.1M
Investing
$6.3M
Financing
$42.4M
MAZE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MAZE vs Biotech Stocks
Maze Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.